Kirstin Perdrizet
Overview
Explore the profile of Kirstin Perdrizet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicholas C, Beharry A, Bendzsak A, Bisson K, Dadson K, Dudani S, et al.
Cancers (Basel)
. 2024 Jul;
16(14).
PMID: 39061145
Liquid biopsy is rapidly becoming an indispensable tool in the oncologist's arsenal; however, this technique remains elusive in a publicly funded healthcare system, and real-world evidence is needed to demonstrate...
2.
Lau S, Perdrizet K, Fung A, Mata D, Weiss J, Holzapfel N, et al.
JTO Clin Res Rep
. 2023 Sep;
4(10):100562.
PMID: 37744308
Introduction: NSCLC with exon 14 skipping mutation (ex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore,...
3.
Sheffield B, Beharry A, Diep J, Perdrizet K, Iafolla M, Raskin W, et al.
Curr Oncol
. 2022 Mar;
29(3):1326-1334.
PMID: 35323313
: Biomarker data are critical to the delivery of precision cancer care. The average turnaround of next-generation sequencing (NGS) reports is over 2 weeks, and in-house availability is typically limited...
4.
Perdrizet K, Stockley T, Law J, Smith A, Zhang T, Fernandes R, et al.
Cancer Treat Res Commun
. 2022 Mar;
31:100534.
PMID: 35278845
Objectives: Standard molecular testing for patients with stage IV non-small cell lung cancer (NSCLC) in the Canadian publicly funded health system includes single gene testing for EGFR, ALK, and ROS-1....
5.
Perdrizet K, Cheema P
Curr Oncol
. 2021 Dec;
28(6):5408-5421.
PMID: 34940090
The management of Stage III non-small cell lung cancer (NSCLC) is complex and requires multidisciplinary input. Since the publication of the PACIFIC trial (consolidative durvalumab post concurrent chemotherapy and radiation...
6.
Perdrizet K, Sutradhar R, Li Q, Liu N, Earle C, Leighl N
J Thorac Dis
. 2021 Oct;
13(9):5419-5429.
PMID: 34659808
Background: In Canada, epidermal growth factor receptor (EGFR) inhibitor therapies in advanced non-small cell lung cancer (NSCLC) were initially approved regardless of status. The purpose of this study is to...
7.
Perdrizet K, Leighl N
Curr Treat Options Oncol
. 2019 Feb;
20(3):21.
PMID: 30778772
The treatment of advanced non-small cell lung cancer (NSCLC) has evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected patients in the first-line setting. Angiogenesis inhibitors have...
8.
Fernandes R, Mazzarello S, Stober C, Ibrahim M, Dudani S, Perdrizet K, et al.
J Glob Oncol
. 2018 Sep;
4:1-8.
PMID: 30241156
Purpose: Despite widespread use of fluorouracil, epirubicin, cyclophosphamide, docetaxel (FEC-D) chemotherapy in breast cancer, the optimal strategy for primary febrile neutropenia (FN) prophylaxis remains unknown. A systematic review was therefore...
9.
Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim M, et al.
Breast Cancer Res Treat
. 2016 Oct;
161(1):1-10.
PMID: 27783280
Background: Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF)...
10.
Reinglas J, Perdrizet K, Ryan S, Patel R
Clin Exp Gastroenterol
. 2016 Oct;
9:301-305.
PMID: 27703390
Splenosis, the autotransplantation of splenic tissue following splenic trauma, is uncommonly clinically significant. Splenosis is typically diagnosed incidentally on imaging or at laparotomy and has been mistakenly attributed to various...